Abstract: The disclosure relates to cyclopropyl derivatives and methods of use. In some embodiments, the disclosure relates to methods of managing medical disorders with pharmaceutical compositions disclosed herein administered to subject in need thereof. In certain embodiments, the disclosure relates to methods of managing mental disorders, mood disorders, pain, and fibromyalgia and related conditions with pharmaceutical compositions disclosed herein.
Type:
Grant
Filed:
May 3, 2016
Date of Patent:
February 19, 2019
Assignees:
Emory University, Wake Forest University Health Services
Inventors:
Huw M. L. Davies, Spandan Chennamadhavuni, Thomas J. Martin, Steven R. Childers
Abstract: It is disclosed herein that ssAAV and scAAV vectors of the same serotype administered by injection into the cerebrospinal fluid (CSF) via the intracerebroventricular (ICV) or intrathecal (cisternal or lumbar) route exhibit different cellular tropisms in the central nervous system. Thus, a subject can be treated by injection into the CSF of ssAAV or scAAV vector encoding a therapeutic protein, such as an ssAAV9 or scAAV9 vector. The therapeutic protein can be targeted to specific cells using these vectors. In some embodiments, scAAV9 is utilized to achieve superior transduction in the hippocampus, cerebellum and cerebral cortex where both neurons, particularly Purkinje neurons, and glial cells (such as astrocytes) are transduced. In other embodiments, ssAAV9 is utilized to minimize transduction of astrocytes. In further embodiments, an immunosuppressive agent is also administered to the subject.
Abstract: This disclosure relates to extracts from chestnut plants and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the leaves of a Castanea plant. In certain embodiments, the disclosure relates to methods of treating or preventing bacterial infections, acne, and other related uses.
Type:
Grant
Filed:
June 24, 2016
Date of Patent:
February 5, 2019
Assignees:
Emory University, University of Iowa Research Foundation
Inventors:
Cassandra L. Quave, James Lyles, Alexander R. Horswill
Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.
Type:
Application
Filed:
February 15, 2018
Publication date:
January 31, 2019
Applicants:
Emory University, Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
Inventors:
Rafi Ahmed, Rama Amara, Gordon Freeman, Arlene Sharpe, Daniel Barber, E. John Wherry, Sang-Jun Ha
Abstract: Provided are devices, systems, and methods for targeted administration of therapeutic agents to a subject. For example, provided are devices, systems, and methods for targeting the administration of peri-urethral bulking agents.
Abstract: This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant polypeptide or variant disclosed herein to a subject in need thereof.
Type:
Grant
Filed:
April 30, 2015
Date of Patent:
January 1, 2019
Assignee:
Emory University
Inventors:
Brantley R. Herrin, Max Dale Cooper, Rudolf Ehrhardt
Abstract: A device may be configured to allow individual measuring of at least one property of at least one cell, such as measuring a contraction force of a platelet. The device may include a plurality of wells. Each well may include a hydrogel layer, the hydrogel layer including a hydrogel having a top surface that includes a pattern of cell interaction regions. The wells may differ in stiffness properties of the hydrogel and/or biochemical conditions. Each cell interaction region may include a group of at least two cell interaction sites. The spacing between each cell interaction region may be greater than a spacing between the at least two cell interaction sites of each cell interaction region. In this way, cell-cell interactions may be reduced and thereby increasing number of individual cells capable of being measured.
Type:
Grant
Filed:
March 10, 2014
Date of Patent:
January 1, 2019
Assignees:
Emory University, Children's Healthcare of Atlanta, Inc.
Inventors:
Wilbur A. Lam, David Myers, Yongzhi Qiu
Abstract: This disclosure relates to particles conjugated to therapeutic nucleic acids. In certain embodiments, the nucleic acid comprises a sequence that catalytically cleaves RNA, e.g., DNAzyme or RNAzyme. In certain embodiments, the particles contain nucleic acids with both DNAzyme and/or RNAzyme and siRNA sequences. The cleaving nucleic acids optionally comprise a sequence functioning to hybridize to a target of interest and/or the particles are further conjugated to a targeting moiety. In certain embodiments, conjugated particles are used in the treatment or prevention of cancer or viral infections or bacterial infections. In certain embodiments, conjugated particles are used in detecting metal ions and other small molecule analyte.
Abstract: In certain embodiments, this disclosure relates to methods of treating or preventing HvGD comprising administering an effective amount of indole-2-carboxyaldehyde, indole-3-carboxyaldehyde, or derivative to a subject in need thereof. In certain embodiments, this disclosure relates to methods of treating a subject with a hematological malignancy or other cancer comprising transplanting allogenic bone marrow or stem cells in combination with administering an effective amount of an indole-2-carboxyaldehyde, indole-3-carboxyaldehyde, or derivative thereof to a subject in need thereof.
Type:
Grant
Filed:
September 17, 2016
Date of Patent:
December 18, 2018
Assignee:
Emory University
Inventors:
Daniel Kalman, Edmund K. Waller, Cynthia R. Giver, Alyson Swimm, Sravanti Rangaraju
Abstract: This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.
Type:
Grant
Filed:
September 10, 2014
Date of Patent:
December 11, 2018
Assignee:
Emory University
Inventors:
Dennis C. Liotta, George R. Painter, Gregory R. Bluemling, Abel de la Rosa
Abstract: The devices and methods relate to devices for stabilizing and/or positioning tissue (e.g., heart) within a surgical area. The device may include an articulating arm and a tissue stabilizing member. The device may include one or more stabilizing segments disposed along at least a portion of the length of the articulating arm. Each stabilizing segment may be configured to compress and expand with respect to an internal channel of the arm. The articulating arm may be configured to move between a fixed state and movable state based on a state of the one or more stabilizing segments. In the fixed state, the one or more stabilizing segments may be compressed against the internal channel. In the movable state, the one or more stabilizing segments may be expanded with respect to the internal channel.
Abstract: Disclosed herein are recombinant viral vectors comprising a liver specific promotor in operable combination with a heterologous nucleic acid sequence encoding a protein, such as a clotting factor. Methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B, are also provided.
Type:
Application
Filed:
August 8, 2018
Publication date:
December 6, 2018
Applicants:
Emory University, Children's Healthcare of Atlanta, Inc.
Inventors:
Christopher B. Doering, H. Trent Spencer, Harrison C. Brown
Abstract: Nanostructures, methods of preparing nanostructures, methods of detecting targets in subjects, and methods of treating diseases in subjects, are disclosed. An embodiment, among others, of the nanostructure includes a metallic gold surface-enhanced Raman scattering nanoparticle, a Raman reporter and a protection structure. The protection structure may include a thiol-polyethylene glycol to which may be attached a target-specific probe.
Type:
Grant
Filed:
November 19, 2012
Date of Patent:
November 27, 2018
Assignee:
Emory University
Inventors:
Ximei Qian, Dominic Ansari, Shuming Nie
Abstract: This disclosure relates to chimeric respiratory syncytial virus (RSV), live attenuated vaccine and immunogenic compositions, and methods of use. In certain embodiments, the chimeric respiratory syncytial virus has a mutated gene pattern encoding an RSV F protein having M at position 79, R at position 191, K at position 357, and/or Y at position 371.
Abstract: This disclosure relates to synthetic coupling methods using catalytic molecules. In certain embodiments, the catalytic molecules comprise heterocyclic thiolamide, S-acylthiosalicylamide, disulfide, selenium containing heterocycle, diselenide compound, ditelluride compound or tellurium containing heterocycle. Catalytic molecules disclosed herein are useful as catalysts in the transformation of hydroxy group containing compounds to amides, esters, ketones, and other carbon to heteroatom or carbon to carbon transformations.
Abstract: In certain embodiments, this disclosure relates to conjugates comprising a polypeptide of GM-CSF and a polypeptide IL-4. Typically, the GM-CSF and IL-4 are connected by a linker, e.g., polypeptide. In certain embodiments, the disclosure relates to isolated nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such nucleic acids.
Type:
Grant
Filed:
April 19, 2017
Date of Patent:
October 9, 2018
Assignees:
Emory University, Children's Healthcare of Atlanta, Inc.
Abstract: Devices and methods for sternal retraction that reduces bleeding from the cut edges of a sternum and reduces fracturing of the sternum during retraction. The devices and methods involve the use of sternal retractor blades having a certain geometry and inserts placed inside the sternal retractor blades during retraction of the sternotomy incision. The blades and inserts act to tamponade the blood flow from the cut sternal edge and reduce fracturing of the sternum during retraction.
Type:
Grant
Filed:
February 20, 2017
Date of Patent:
October 9, 2018
Assignee:
Emory University
Inventors:
John D. Puskas, Kelly Kloster Hon, Erick Eladio Rio, Brian Wong-Shui, Mark Joseph Moneypenny
Abstract: The disclosure relates to TAK1 inhibitors, compositions, and uses related thereto. In certain embodiments, the disclosure relates to compounds of formula I, pharmaceutical compositions having a compound of formula I, and methods of treating or preventing cancer by administering an effective amount of a pharmaceutical composition having a compound of formula I to a subject in need thereof.
Type:
Grant
Filed:
September 4, 2017
Date of Patent:
October 9, 2018
Assignee:
Emory University
Inventors:
Huw M. L. Davies, Spandan Chennamadhavuni, Andrei Bakin
Abstract: This disclosure relates to specific binding agents, such as isolated recombinant monoclonal antibodies, that bind Glycoprotein Ib alpha (GPIba). More specifically, the disclosure relates to methods of preventing platelet ectodomain shedding, preventing platelet clearance and degradation, maintaining and increasing platelet blood serum levels for in vitro or in vivo applications. In some embodiments, the disclosure relates to the production, diagnostic use, and therapeutic use of monoclonal and polyclonal antibodies, and the antigen-binding fragments thereof, which specifically bind GPIba. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies for specific binding agent. Compositions and methods for inhibiting shedding, clearance, or degradation, or treating diseases associated with GPIba ectodomain shedding are also described.
Type:
Grant
Filed:
February 3, 2014
Date of Patent:
September 25, 2018
Assignees:
Emory University, Children's Healthcare of Atlanta, Inc.
Abstract: This disclosure relates to a GM-CSF and IL-4 conjugate fused to a glycolipid (GPI)-anchoring sequence that is incorporated into chimeric virus-like particles (VLPs) enriched with a viral protein, e.g., viral envelope protein or HIV envelope protein. In certain embodiments, the disclosure relates to methods of immunization with the chimeric VLPs disclosed herein. In certain embodiments, the disclosure relates to methods of immunization with disclosed HIV antigen containing VLPs through an intramuscular priming-intranasal boosting immunization route.
Type:
Grant
Filed:
April 29, 2016
Date of Patent:
September 11, 2018
Assignees:
Emory University, Children's Healthcare of Atlanta, Inc.
Inventors:
Baozhong Wang, Richard W. Compans, Jacques Galipeau, Jiusheng Deng